CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.
Genova, Italy. In Expert Rev Clin Immunol, Jan 2016
The cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA-4-Ig: abatacept) that selectively modulates the CD28:CD80/86 co-stimulation signal appears a biologic DMARD interacting with T cells but also with other cell populations involved in RA pathophysiology.
Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection.
A Coruña, Spain. In Curr Pharm Des, Jan 2016
Different CNS disorders, such as anxiety, depression, psychosis, stroke, Alzheimer's disease, Parkinson's disease, attention-deficit hyperactivity disorder, migraine, epilepsy, vascular dementia, mental retardation, cerebrovascular encephalopathy, multiple sclerosis, brain tumors, cranial nerve neuropathies, mental retardation and post-traumatic brain injury exhibit changes in CD3, CD4, CD7, HLA-DR, CD25, CD28, and CD56 immune markers.
[Immunotherapy in head and neck cancer].
Essen, Germany. In Hno, Nov 2015
Monoclonal antibodies directed specifically toward T cell-stimulating receptors such as CD28 and CD134, or immunosuppressive receptors CTLA-4 and PD-1, are currently under investigation and have shown promising results.
Shifting the Evolving CAR T Cell Platform into Higher Gear.
San Francisco, United States. In Cancer Cell, Nov 2015
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cells to show that CD28-CD3ζ CAR T cells that constitutively express 4-1BBL promote T cell expansion and tumor eradication while reducing exhaustion.
[Immunological Aspects in Oncology--Circulating γδ T Cells].
More papers using
In Klin Onkol, 2014
Detailed immunophenotyping was also conducted describing representation of memory subsets (using CD45RO and CD27 markers) and presence of surface markers HLADr, CD69, CD25, CD28, CCR7, CTLA 4, ICOS, PD 1L and PD 1 between γδ T cells of the controls and breast carcinoma patients.
GATA-3 in Human T Cell Helper Type 2 Development
In The Journal of Experimental Medicine, 1990
... anti-CD4 (Sigma-Aldrich); anti-CD19 and FITC-labeled anti–HLA-DR (DakoCytomation); PE-labeled anti–IL-4 (MP4-25D2), FITC-labeled anti–IFN-γ (4S.B3), and anti-CD28 (CD28.2;